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Maria Carmela Latella1, Fabienne Cocchiarella1, Laura De Rosa1, Giandomenico Turchiano1,†,
Manuel A.F.V. Gonçalves2, Fernando Larcher3,4,5, Michele De Luca1 and Alessandra Recchia1Recessive dystrophic epidermolysis bullosa (RDEB) is caused by defects in type-VII collagen (C7), a protein
encoded by the COL7A1 gene and essential for anchoring fibril formation at the dermal-epidermal junction.
Gene therapy of RDEB is based on transplantation of autologous epidermal grafts generated from gene-
corrected keratinocytes sustaining C7 deposition at the dermal-epidermal junction. Transfer of the COL7A1
gene is complicated by its very large size and repetitive sequence. This article reports a gene delivery approach
based on the Sleeping beauty transposon, which allows integration of a full-length COL7A1 cDNA and
secretion of C7 at physiological levels in RDEB keratinocytes without rearrangements or detrimental effects on
their clonogenic potential. Skin equivalents derived from gene-corrected RDEB keratinocytes were tested in a
validated preclinical model of xenotransplantation on immunodeficient mice, where they showed normal
deposition of C7 at the dermal-epidermal junction and restoration of skin adhesion properties. These results
indicate the feasibility and efficacy of a transposon-based gene therapy approach to RDEB.
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Recessive dystrophic epidermolysis bullosa (RDEB) is charac-
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due to loss of functionmutations in theC7gene (COL7A1). There
are no curative therapies for RDEB, and the care of patients is
palliative and restricted to the treatment of individual wounds
(Ly and Su, 2008; Mellerio et al., 2007). Experimental therapies
under development include recombinant C7 protein
(Remington et al., 2008; Woodley et al., 2004; Woodley et al.,
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plantation (Tolar andWagner, 2012), and gene therapy (Murauer
et al., 2015). Current ex vivo gene therapy approaches, based on
autologous transplantation of genetically corrected epidermal
grafts, aim at transferring the correct, full-lengthCOL7A1 cDNA
(w9 kb) in keratinocyte stem cells by oncoretroviral or lentiviral
vectors (Droz-Georget Lathion et al., 2015; Jackow et al., 2016;
Sebastiano et al., 2014; Siprashvili et al., 2010; Titeux et al.,
2010). These vectors are associated with a certain risk of inser-
tional mutagenesis and have limited cargo capacity, resulting in
genomic instability and rearrangements when used to transfer
largeC7expressioncassettes (Droz-Georget Lathionet al., 2015;
Titeux et al., 2010). Recently, Georgiadis et al. (2015) codon-
optimized the C7 cDNA cloned into a self-inactivating lenti-
viral vector and showedexpressionof anormally sizedprotein in
94% of transduced RDEB fibroblasts. Targeted exon skipping
and nuclease-mediated surgical genomic correction of specific
mutations in the C7 coding sequence is an emerging approach
(Chamorro et al., 2016; Osborn et al., 2013; Turczynski et al.,
2016). Although this finding represents a promising patient-
specific therapy, it has to cope with the low efficiency of ho-
mologous recombination in primary cells (Coluccio et al., 2013;
Duarte et al., 2014), which requires selection/enrichment of the
genome-edited cells before graft generation and transplantation.
As an alternative approach, we investigated the feasibility of
ex vivo COL7A1 gene replacement by delivering a full-length
COL7A1 cDNA to graft-maintaining keratinocytes from RDEB
patients by the Sleeping beauty (SB) transposon system. The
system is based on the use of a previously described pT2uthors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
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(SB100X) (Mates et al., 2009), which can mediate precise cut-
and-paste transposition of gene expression cassettes in a vari-
ety of human cells (Ivics and Izsvak, 2015) and in a clinical
setting (Singh et al., 2014). Although the efficacy of transposase-
mediated transgene insertion decreases with increasing cargo
size (Turchiano et al., 2014), the hyperactive SB100X trans-
posase has no strict size limits and canmediate the transposition
of relatively large (>10 kb) DNA fragments without rearrange-
ments (Escobar et al., 2016). The SB transposon integration
pattern is almost random and potentially safer than that of
retroviral vectors (Turchiano et al., 2014). We incorporated a
COL7A1 expression cassette in the T2 transposon and provided
the SB100X cassette in trans by plasmid transfection in an
immortalized, patient-derived RDEB keratinocyte cell line
(iRDEB) (Chamorro et al., 2013). Molecular characterization of
single, transposed iRDEB clones showed the SB-mediated
integration of the full-length COL7A1 transposon and a
complete restoration of full-size C7 protein expression. To
transpose the COL7A1 cassette in primary clonogenic
RDEB keratinocytes, which are resistant to plasmid trans-
fection, we developed an adenoviral (AdV) vector platform
consisting in a helper-dependent (HD) AdV vector carrying
the transposon cassette flanked by flippase recognition target
(FRT) sites (AdVHDC7.F50), a second-generation vector (i.e.,
E1- and E2A-deleted) coding for enhanced flippase (FLPe)
recombinase (AdVD2FLPe.F50), and a first-generation AdV
vector (i.e., E1-deleted) coding for the SB100X transposase
(AdVD1SB100X.F50). All AdVs are independent of the coxsackie
and adenovirus receptor to enter target cells owing to a fiber
modification inwhich the apical receptor-interactingmotifs are
derived from adenovirus serotype 50 (F50) instead of prototypic
serotype 5 (Janssen et al., 2013; Knaan-Shanzer et al., 2001).
We used this combination of AdV platforms to infect primary
RDEB keratinocytes carrying the recurrent mutation 497insA in
the COL7A1 gene, which generates premature stop codon in
exon 5 and no C7 expression (Gardella et al., 1999). Infection
with the three different types of vectors did not affect the clo-
nogenic potential of RDEB keratinocytes and restored C7
expression in vitro. The infected keratinocyte bulk population
was used to generate skin equivalents that were grafted on
immunodeficientmice, which showed C7 secretion, functional
reconstruction of the dermal-epidermal junction, and restora-
tion of adhesion properties in a validated preclinical model of
human epidermis in vivo.
RESULTS
SB-mediated transposition of a full-length human COL7A1
cDNA in iRDEB keratinocytes
The SB100X and the T2-based transposon were exploited to
investigate the restoration of C7 expression in patient-
derived, iRDEBs carrying null mutations in the COL7A1
gene. The transposon cassette carried the full-length COL7A1
cDNA (pLRZScol7) (Baldeschi et al., 2003) under the phos-
phoglycerokinase promoter (pT2C7) (Figure 1a). We trans-
fected iRDEB with pT2C7 in the presence or absence of the
SB100X transposase-expressing plasmid. Transfection effi-
ciency was w20% in both samples 2 days after transfection,
as assayed by immunofluorescence for C7 expression
(Supplementary Figure S1a online). Twenty-one days aftertransfection, the culture transfected with pT2C7þpSB100X
contained approximately 7% C7þ cells, whereas control cells
were negative for C7 expression (Figure 1b and
Supplementary Figure S1a). Transposed gene expression was
tested in the bulk cell population by reverse tran-
scriptaseePCR: iRDEB cells express background levels of
COL7A1 mRNA that do not result in mature protein synthesis
(Chamorro et al., 2013), whereas a significant COL7A1
mRNA expression over the background was detected in cells
transfected with pT2C7þpSB100X (Supplementary
Figure S1b online). We then cloned by limiting dilution the
transposed iRDEB bulk culture and found 14 single clones
positive for C7 cDNA (Supplementary Figure S2 online). Then
we assessed by RT-PCR the expression of phosphoglycer-
okinase -driven C7 cDNA in randomly selected 8 of 14
clones (Supplementary Figure S3 online). Vector copy num-
ber and the integrity of the transposed cassette were tested by
Southern blot analysis, after digesting genomic DNAs with
BglII and DraIII or HindIII, respectively. Hybridization with a
C7-specific probe released bands longer than 2.3 kb at the
time of BglII digestion and 1.9kb at the time of DraIII diges-
tion, indicating an average vector copy number of 1.5
(Figure 1c). The 10-kb band present at the time of HindIII
digestion showed that transposition occurred without rear-
rangement in the 3’ (Figure 1d) and 5’ end of collagen VII
cDNA (Supplementary Figure S4 online). To unequivocally
prove that the COL7A1 integrants resulted from SBemedi-
ated transposition events, we mapped the insertion sites using
a modified version of the linker-mediated PCR technique able
to preferentially map the junction between the left-inverted
repeat and the human genome (Turchiano et al., 2014)
(Supplementary Table S1 online; Supplementary Figure S5
online). Bioinformatics analysis of modified linker-mediated
PCR amplicons (Supplementary Figures S6 and S7 online)
showed only one bidirectional mapping of the single trans-
poson copy hosted by clone 7. To confirm that in all other
clones the left-inverted repeategenome junction was prefer-
entially amplified by the modified linker-mediated PCR,
we designed specific primers on the genomic regions flanking
the right-inverted repeats. In all hits but one (9.2) we found
the preference for the amplification of left-inverted
repeategenome junction obtained by modified linker-
mediated PCR technique (Supplementary Figure S8 online).
Most importantly, all the 10 transposon hits belonging to 8
clones showed the TA di-nucleotides signature of SB-mediated
transposition without genomic rearrangements, deletions, or
insertions in the target sites (Supplementary Figure S5).
Finally, we verified the production of intracellular and
secreted C7 mature protein by Western blot analysis
(Figure 1e, upper and lower panels). All clones tested
expressed a C7 protein of normal size. All together, these data
show that the SB-mediated transposition allows integration of
intact copies of the large COL7A1 cDNA at low numbers in
C7-deficient keratinocytes and the expression and secretion
of a normal C7 protein.
Restoration of C7 expression in primary recessive dystrophic
epidermolysis bullosa keratinocytes
Despite the significant potential of the SB-mediated trans-
position system, plasmid transfection of the transposon/www.jidonline.org 837
Figure 1. C7 transposition in iRDEB
keratinocytes. (a) Schematic outline of
pT2C7 and pSB100X plasmids. The
black arrows represent the IR of the
transposon. (b) pT2C7-transfected
iRDEB in presence or in absence of
pSB100X. C7þ cells scored by
immunofluorescence 2 and 21 days
after transfection. (c) Southern blot on
iRDEB clones. BglII (left panel) and
DraIII (right panel) digested DNA
hybridized to a C7-specific probe.
Dotted lines represent human
genome. (d) Southern blot on iRDEB
clones. HindIII digested DNA probed
with a C7-specific probe. Black bars
indicate C7-specific probe. Black
arrows indicate endogenous signal. (e)
Western blot analysis on total extracts
(upper panel) and on culture
supernatants (lower panel) of iRDEB-
transposed clones. Vinculin represents
internal loading control. CMV,
cytomegalovirus; iRDEB,
immortalized recessive dystrophic
epidermolysis bullosa; NC, not
treated; PC, wild-type keratinocytes;
PGK, phosphoglycerate kinase.
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838transposase components in primary RDEB keratinocytes is
inefficient and toxic (Supplementary Figure S9 online) and
remains an obstacle to its practical application in gene therapy.
To overcome this limitation, we delivered the SB100X trans-
posase and the pT2C7 transposon via the infection of target
cells with AdVD1SB100X.F50 and AdVHDC7.F50, respectively.
To ameliorate the transposition efficiency we avail the FRT/
FLPe recombinase (Zhang et al., 2013), flanking the C7
expression cassette by the FRT sites and providing the FLPe
recombinase by infecting target cells with AdVD2FLPe.F50
(Figure 2a). RDEBkeratinocyteswere isolated froma small skinJournal of Investigative Dermatology (2017), Volume 137biopsy obtained from a 23-year-old patient carrying a homo-
zygous mutation (497insA) in the COL7A1 gene, which gen-
erates a premature stop codon in exon 5 and no C7 expression
at protein level. Positive staining for p63 indicates the presence
of highly clonogenic, progenitor/stem cells (Figure 2b)
(Gardella et al., 1999; Pellegrini et al., 2001; Senoo et al.,
2007). Moreover, the clonogenic ability of RDEB keratino-
cytes (not infected and AdVs-infected) and healthy epidermal
cultures are similar (Figure 2c).
RDEB keratinocytes were cultivated onto a feeder of
irradiated 3T3-J2 cells, according to standard procedures
Figure 2. Characterization of
adenoviral vectors and human
primary keratinocytes from RDEB
patient. (a) Schematic representation
of the adenoviral vectors used.
AdVHDC7.F50 represents the HD
adenoviral vector bearing the T2C7
transposon flanked by FRT sites.
AdVD1SB100X.F50 and AdVD2FLPe.F50
represent the first- and second-
generation adenoviral vectors carrying
the transposase SB100X and FLPe
recombinase, respectively. (b)
Immunofluorescence for C7 (green)
and p63 (red) expression in wild-type
and RDEB keratinocytes. Scale bar ¼
20 mm. (c) CFE assays performed on
WT, NI, and AdVs-infected RDEB
keratinocytes (Ad Vectors) two
passages after infection. CFE, colony-
forming efficiency; FRT, flippase
recognition target; HD, helper
dependent; NI, not infected; RDEB,
recessive dystrophic epidermolysis
bullosa; WT, wild type.
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Correction of RDEBused for cell therapy of third-degree burn wounds (Pellegrini
et al., 1999; Ronfard et al., 2000). RDEB keratinocytes were
infected as a passage 3 mass culture with a suspension of Ad
vectors encoding C7, SB100X, and FLPe at MOI 250, 1000,
1000, respectively (Supplementary Figure S10 online).
Immunofluorescence analysis of infected RDEB keratino-
cytes found a robust infection with the AdVHDC7.F50 and
AdVD1SB100X.F50 vectors (Figure 3a). To demonstrate that
the infection by Ad vectors did not affect the clonogenic
potential of RDEB keratinocytes, we cultivated serially
infected, uninfected cells and wild-type keratinocytes and
calculated the number of cell doublings. As shown in
Figure 3b, uninfected (black line) and genetically modified
(red lines) RDEB keratinocytes exhibit similar population
doublings and growth potentials, which were comparable to
those of two healthy controls (grey lines). Accordingly,
clonal conversion and progressive appearance of abortedcolonies were similar in RDEB (uninfected and infected)
and healthy epidermal cultures (data not shown).
In AdVs infected cells, the ratio between clonogenic and
abortive colonies was not altered (Figure 3c). Colony-forming
efficiency and C7-specific immunofluorescence analysis per-
formed onAdVs-infected keratinocytes indicated the presence of
clonogenic C7þ colonies (Figure 3d). Six cell doublings (almost
15 days) after AdVs infection, immunofluorescence analysis
found that transposition could be attained not only in p63-
positive cells but in all types of clonogenic cells (Pellegrini
et al., 2001; Senoo et al., 2007) (Figure 3e). The frequency of
p63þC7þ colonies (29 of 34) scored in 4 different experiments
was 85% and correlates with the frequency of p63þ colonies in
uninfected RDEB keratinocytes (41 of 50; 82%). The presence of
C7 expression was followed up to 17 days after infection by
quantitative real-time reverse transcriptase PCR and C7 cDNA
was followed over time up to P9 (42 days after infection) by PCRwww.jidonline.org 839
Figure 3. Restoration of full-length
C7 protein expression in
keratinocytes from RDEB patient. (a)
Images of immunofluorescence on C7
and SB100X in RDEB keratinocytes
upon AdV infection. (b) Population
doublings underwent by two normal
donors (WT 1 and 2; grey line), RDEB
keratinocytes infected with AdVs (red
line), and NI cells (black line). (c)
Number of clonogenic (dashed line)
and abortive colonies over the total
colonies are reported in AdVs-infected
cells (red line) and in NI cells (black
line). (d) Digital image shows colonies
of AdVs-infected keratinocytes. C7
expression in two transposed RDEB
keratinocyte colonies are indicated by
white arrows. Scale bar ¼ 200 mm (e)
C7 (green) and p63 (red) expression in
two C7-transposed colonies. Scale
bar ¼ 20 mm. NI, not infected; RDEB,
recessive dystrophic epidermolysis
bullosa; WT, wild type.
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840(SupplementaryFigure S11online). Tocalculate theproportionof
transposed clones, we serially diluted the AdV-treated (i.e.,
AdVHDC7.F50 þ AdVD1SB100X.F50 þ AdVD2FLPe.F50) bulk
population 7 days after infection (3 cell doublings) to minimize
the residual level of unintegrated AdVHDC7.F50 vector, and
expanded48clones that underwentmore than20cell doublings.
Three clones (6%) resulted positive for the integration of C7
cDNA and negative for AdV backbone by PCR analysis
(Supplementary Figure S12a and b online).
Functional correction of recessive dystrophic epidermolysis
bullosa in vivo by transposed COL7A1 keratinocytes
To determine whether secreted C7 produced by COL7A1-
transposed keratinocytes can restore the dermal-epidermal
junction in vivo, we generated skin equivalents with a bulkJournal of Investigative Dermatology (2017), Volume 137culture of transposed RDEB keratinocytes, and grafted them
on the dorsal region of immunodeficient (nu/nu) mice, as
previously described (Larcher et al., 2007; Gache et al.,
2004). Primary RDEB keratinocytes were infected with
AdVs as describe above. Ten days after infection, the culture
was plated on fibrin matrix to prepare 11 transplantable hu-
man skin equivalents to be grafted on 11 immunodeficient
mice. Six of 11 mice that received the genetically modified
skin equivalents were successfully grafted. Two mice died for
reasons not related to the xenograft. The grafts from 4 mice
were analyzed macroscopically, histologically, and molecu-
larly 6, 10, and 12 weeks after transplantation, a time by
which approximately 1.5 to 3 epidermal turnover cycles had
occurred (Duarte et al., 2014). In Figure 4 we reported the
results of 4 mice from 6 to 12 weeks after transplant.
Figure 4. Transplantation of C7-
transposed human RDEB
keratinocytes onto mice. (a) Engrafted
mouse shows human regenerated skin
(white dashed area, left panel; scale
bar ¼ 1.6 mm) 6 weeks after grafting.
Red dashed squares (right panel; scale
bar ¼ 1.1mm) indicate two blisters
upon dissection (central panel; scale
bar ¼ 1.6mm). (b) Immunofluores-
cence analysis for the detection of
human C7 and Pan keratin expression
in sections of 6-week-old graft (mouse
#1). Dotted line borders the mouse
and the engrafted human skin. (c)
Immunofluorescence analysis for the
detection of human C7 in sections of
10-week-old graft (mouse #2 and #3)
and 12-week-old graft (mouse #4).
White arrows indicate blister areas. (d)
WT human and mouse skin are
positive and negative controls,
respectively. Scale bar ¼ 50 mm. (e)
PCR analysis on 5’, 3’, and C of the C7
cDNA in NC RDEB keratinocytes, in
pregraft C7-transposed bulk
population, and in biopsies from mice
#1, #2, and #4. *Unspecific signals. C,
central region; NC, not treated; RDEB,
recessive dystrophic epidermolysis
bullosa; WT, wild type.
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(Figure 4a, left panel), and skin biopsy samples from engraf-
ted skin were isolated for histologic examination and for PCR
analysis to confirm C7 transgene integration. The macro-
scopic analysis found regeneration of a human skin with
typical histologic architecture. Upon surgical dissection(Figure 4a, central panel), we observed derma-epidermal
blister formations in two areas (Figure 4a, right panel), indi-
cating the absence of C7 deposition in those areas. This
finding was confirmed by immunofluorescence analysis with
C7 and pan-keratin species-specific antibodies that confirm
the human derivation of the grafted area and thewww.jidonline.org 841
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842nonhomogenous C7 deposition in the derma-epidermal
layer. As reported in Figure 4b, deposition of C7 in mouse
1, 6 weeks after graft, stained all along the section with the
exception of some small area probably corresponding to the
blisters. Human C7þ staining was also observed in sections
from mouse 2, 3, and 4, 10 and 12 weeks after grafting
(Figure 4c), similarly to what obtained with wild-type human
skin and differently from the mouse skin (Figure 4d). Blister
areas were observed in all mice independently from the time
points after graft. Molecular analysis of the human skin from
mouse 1, 2, and 4 from 6 to 12 weeks after grafting,
respectively, showed PCR-amplified bands accounting for the
full-length C7 transgene (Figure 4e) indicating absence of
gene rearrangement events in vivo. Qualitative and quanti-
tative PCR signals from the HD-Ad vector backbone
(Supplementary Figure S13 online) ruled out long-term
persistence of the AdVHDC7.F50 vector in vivo. Collectively,
these data provide evidence that human C7 expression from
a polyclonal population of COL7A1-transposed keratinocytes
can be achieved in vivo, contributing to restore the dermal-
epidermal junction and adherence of the skin to the dermis.
DISCUSSION
Dystrophic epidermolysis bullosa is a severe monogenic
genodermatosis caused by mutations in the COL7A1 gene.
The phenotypic variability of dystrophic epidermolysis bul-
losa depends on the types of mutations in COL7A1 gene as
well as on their position along the gene. The full spectrum of
gene mutations in dystrophic epidermolysis bullosa remains
elusive; thus, patient-tailored gene correction therapy repre-
sents a difficult task. Among the therapeutic strategies for
RDEB, autologous transplantation of genetically corrected
keratinocytes is a promising approach, which has been suc-
cessfully exploited in the case of another skin adhesion
defect, the LAMB3-deficient junctional epidermolysis bullosa
(De Rosa et al., 2014; Mavilio et al., 2006). Gene correction
of autologous RDEB keratinocytes has been obtained by
stably integrating the full-length COL7A1 cDNA by murine
leukemia virus or HIV-derived retroviral vectors, which,
however, led to significant transgene rearrangement and
expression of C7 of abnormal size, which could not be
completely controlled even in the best cases (Georgiadis
et al., 2015). The presence of numerous repeated se-
quences in the w9-kb-long COL7A1 cDNA may trigger
rearrangements during the retrotranscription process and the
integration of truncated or incomplete proviruses into the
host cell genome. An alternative approach is the use of DNA-
based integration systems, such as transposition of DNA
expression cassettes by the SB transposon and the engi-
neered, hyperactive SB100X transposase, which was suc-
cessfully used in the past to integrate relatively large
expression cassettes in a variety of human cells (Mates et al.,
2009; Escobar et al., 2016). The SB-mediated approach was
also used in 2003 (Ortiz-Urda et al., 2003) to correct LAMB3-
deficient junctional epidermolysis bullosa in vitro and in vivo
upon xenotransplantation of gene-corrected human skin on
immunodeficient mice. With respect to SB components used
by Ortiz-Urda et al. (2003), we used the hyperactive SB100X
transposase (Mates et al., 2009) and a new version of trans-
poson IR, called T2 (Cui et al., 2002; Geurts et al., 2003)Journal of Investigative Dermatology (2017), Volume 137improve stable gene transfer of the large collagen VII cDNA
in human RDEB keratinocytes without drug selection.
In this study, we generated a T2-based transposon plasmid
carrying the full-length COL7A1 cDNA and cotransfected it
with an SB100X transposase plasmid in iRDEB keratinocytes,
leading to about 30% transposition of at least 1 copy per cell
of the COL7A1 transposon. Molecular analysis of individual
keratinocyte clones showed transposase-mediated integration
of intact-size COL7A1 cDNA, which led to intracellular and
secreted C7 protein synthesis at levels comparable to that of
keratinocytes from healthy donors. Southern blot analysis for
the integrity of collagen VII cDNA did not exclude micro-
rearrangements in the coding sequence, although we detec-
ted by western blot analysis a collagen VII protein of
comparable size to that observed in wild-type keratinocytes.
To reproduce the autologous skin transplantation strategy
previously used to correct LAMB3 deficiency in junctional
epidermolysis bullosa patients (Mavilio et al., 2006) in a
preclinical model, we attempted to genetically correct pri-
mary, early passage keratinocytes from a RDEB patient with
the SB transposon-based system. Because human primary
keratinocytes are refractory to physico-chemical transfection,
we vectorized the C7 transposon carrying the COL7A1 gene
and flanked by FRT sites into helper-dependent, also known
as high-capacity, AdV (i.e., AdVHDC7.F50), and the SB100X
transposase into a separate, first-generation AdV (i.e.,
AdVD1SB100X.F50). As previously reported, AdVs represent
the system of choice to transiently and efficiently deliver
genetic material into human keratinocytes without affecting
their clonogenic potential (Coluccio et al., 2013; Chamorro
et al., 2016). Because the mechanism of transposition iden-
tified the circular transposon forms as optimal substrate for
SB-mediated integration (Hausl et al., 2010; Yant et al.,
2002), we developed a second-generation AdV carrying a
FLPe recombinase expression unit (i.e., AdVD2FLPe.F50) to
mediate circularization of the FRT-flanked transposon from
the AdVHDC7.F50 linear genome that can subsequently serve
as a substrate for the SB100X transposase. RDEB keratino-
cytes infected with this AdV-based gene delivery platform
grew in culture and had a cloning efficiency similar to that of
untreated cells, demonstrating the nontoxicity of the delivery
system. Transposition events restored the synthesis of C7
protein expression and secretion in treated iRDEB and
resulted in a transposition of C7 cDNA in 6% of the clono-
genic primary RDEB keratinocytes infected with AdVs. We
detected p63a transcription factor in the C7þ, transposed
colonies, indicating that transposition events may occur in a
progenitor/stem cell compartment.
To show the efficacy of transposition in restoring normal
functional properties in skin derived from transposed RDEB
keratinocytes, we used a validated preclinical model to study
human skin in vivo, based on xenotransplantation of skin
equivalents on immunodeficient mice (Del Rio et al., 2002;
Gache et al., 2004; Larcher et al., 2007; Coluccio et al., 2013;
Duarte et al, 2014). Despite the relatively low number (<10%)
of successfully transposed keratinocytes in the culture obtained
to derive the skin equivalents, we observed that the grafted skin,
clearly demarcated by human-murine junctional boundaries,
contained C7-corrected keratinocytes able to produce and
deposit C7 protein at the dermal-epidermal junction.
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graft maintaining epithelial progenitor/stem cells and that an
in vivo selection effect, most likely caused by competition of
the adhering versus nonadhering keratinocytes, allows
restoration of skin adhesion properties even starting from a
relatively low number of gene-corrected clonogenic cells.
Transposase-mediated integration of full-length COL7A1
cDNA was demonstrated by PCR analysis on genomic DNA
derived from pregraft and postgraft keratinocytes.
This study shows the feasibility of correcting a recurrent
RDEB mutation in human keratinocytes by the SB transposon
integration system safely delivered to keratinocyte progenitor
or stem cells by nonintegrating Ad vectors. This molecular
tool allows the ex vivo manipulation of keratinocytes ob-
tained from RDEB patients’ skin biopsies to generate trans-
plantable human skin for therapeutic purposes. Although the
level of gene correction in clonogenic RDEB keratinocyte is
far from being optimized, the C7 deposition along the dermo-
epidermal junction obtained in our in vivo model was suffi-
cient to sustain skin adhesion. Overall, transposition
efficiency in primary stem cells remains a challenging task.
Efforts should be dedicated to ameliorating the delivery of
circular transposon forms from the adenoviral shuttle by the
FLPe/FRT recombinase or similar systems and in general the
co-infection by different AdVs. Increasing transposition rate
in keratinocyte cultures is necessary to achieve robust levels
of transgene integration in graft-maintaining epithelial pro-
genitor or stem cells, a mandatory prerequisite for clinical
translation of this technology.
MATERIALS AND METHODS
Cell cultures
The cell cultures used in this study are immortalized RDEB kerati-
nocytes (Chamorro et al., 2013), mouse 3T3-J2 fibroblasts (Todaro
and Green, 1963), and wild-type and RDEB human keratinocytes.
Details of culture conditions are reported in Supplementary
Methodology.
Immunofluorescence analysis
Immunofluorescence analysis for C7 expression was performed on
iRDEB, normal donor keratinocytes, RDEB keratinocytes, and skin
biopsies from mice 2e4 using mouse monoclonal LH7.2 antibody
(Sigma-Aldrich, Milan, Italy). Instead for skin biopsy derived from
mouse 1, we used rabbit polyclonal anticollagen VII antibody
(Abcam; Cambridge, United Kingdom) and mouse pan-keratin
antibody (cell signalling). For p63 staining, we used rabbit poly-
clonal p63 antibody (custom made). Immunofluorescence for SB
transposase was performed with the goat SB transposase antibody
(RD Systems; Space Import Export, Milan, Italy). Details of second-
ary antibody and immunofluorescence’s protocol are reported in
Supplementary Methodology.
Bioengineered skin preparation and grafting on
immunodeficient mice
C7-transposed primary keratinocytes were seeded on RDEB
fibroblast-containing fibrin dermal equivalents prepared as previously
described (Larcher et al., 2007; Gache et al., 2004). Briefly, each 9-
cm2 dermal equivalent containing RDEB fibroblasts was seeded
with 5 x 105 keratinocytes. The size of engrafted skin is variable,
although an average area is around 3e4 cm2. Bioengineered skin
equivalents were grafted onto the back of immunodeficient nu/numice (n ¼ 11) according to Del Rio et al. (2002). Successful engraft-
ments occur in 6 of 11 mice. Two mice died for reasons not related to
the graft. Six, 10, and12weeks after grafting, fourmicewere killed and
grafts harvested for skin immunohistochemistry and molecular anal-
ysis. Animal studies were approved by our institutional animal care
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